Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation

Launched by BARTS & THE LONDON NHS TRUST · Dec 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients with long-term persistent atrial fibrillation (AF), a heart condition that causes an irregular heartbeat. Researchers want to compare a method called convergent ablation, combined with the LARIAT procedure, to the standard treatment known as endocardial catheter ablation. This trial aims to see which method works better for managing this condition.

To be eligible for the trial, participants must be between 18 and 80 years old and have had persistent AF for more than a year. They should also have a left atrium size of less than 6 centimeters and be able to provide informed consent. Participants can expect to receive either of the two treatment options and will be monitored closely throughout the study. It's important to note that certain people, such as those with specific heart conditions or previous surgeries, may not qualify for this trial. If you're interested in participating, it could be a chance to help find better treatments for AF while also receiving care for your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years; \< 80 years
• • Persistent AF \> 1-year duration
• • Left atrium size \< 6cm
• • Pts should be able to provide written informed consent.
• Exclusion Criteria:
• • Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments.
• • Subject has a reversible cause of AF or transient AF
• • Subject is absent of LAA or if the LAA is previously surgically ligated
• • Subject has had previous cardiac surgery or abdominal surgery.
• • Subject has contraindication to anticoagulation.
• • Patients with hypertrophic cardiomyopathy.
• • Patients with significant valve disease.
• • Subject has had previous catheter or surgical ablation